RDY vs. TAK, ARGX, BNTX, ONC, TEVA, SMMT, GMAB, ITCI, VTRS, and MRNA
Should you be buying Dr. Reddy's Laboratories stock or one of its competitors? The main competitors of Dr. Reddy's Laboratories include Takeda Pharmaceutical (TAK), argenx (ARGX), BioNTech (BNTX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Viatris (VTRS), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.
Dr. Reddy's Laboratories vs.
Dr. Reddy's Laboratories (NYSE:RDY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, community ranking, valuation and profitability.
Dr. Reddy's Laboratories received 221 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 59.33% of users gave Dr. Reddy's Laboratories an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.
Dr. Reddy's Laboratories has a net margin of 17.25% compared to Takeda Pharmaceutical's net margin of 4.53%. Dr. Reddy's Laboratories' return on equity of 17.87% beat Takeda Pharmaceutical's return on equity.
Dr. Reddy's Laboratories pays an annual dividend of $0.08 per share and has a dividend yield of 0.6%. Takeda Pharmaceutical pays an annual dividend of $0.53 per share and has a dividend yield of 3.8%. Dr. Reddy's Laboratories pays out 12.7% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 132.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Dr. Reddy's Laboratories has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.
In the previous week, Dr. Reddy's Laboratories had 3 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 8 mentions for Dr. Reddy's Laboratories and 5 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.26 beat Dr. Reddy's Laboratories' score of -0.04 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.
3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Dr. Reddy's Laboratories currently has a consensus price target of $17.00, indicating a potential upside of 27.48%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher possible upside, equities research analysts plainly believe Dr. Reddy's Laboratories is more favorable than Takeda Pharmaceutical.
Takeda Pharmaceutical has higher revenue and earnings than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Summary
Dr. Reddy's Laboratories beats Takeda Pharmaceutical on 13 of the 20 factors compared between the two stocks.
Get Dr. Reddy's Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dr. Reddy's Laboratories Competitors List
Related Companies and Tools
This page (NYSE:RDY) was last updated on 2/21/2025 by MarketBeat.com Staff
